Compare Figma Inc. Class A Common Stock (FIG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figma Inc. Class A Common Stock vs Gilead Sciences, Inc. — how do they compare? Figma Inc. Class A Common Stock trades at $22.31 (market cap $11.45B), while Gilead Sciences, Inc. trades at $158.75 (market cap $190.38B). The key difference: Gilead Sciences, Inc. is far larger — about 16.6× Figma Inc. Class A Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.14% dividend while Figma Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and Gilead Sciences, Inc. for 112 Days on average.
| FIG | GILD | |
|---|---|---|
Market Cap | $11.45B | $190.38B |
Volume | 12,424,893 | 5,758,183 |
Sector | Technology | Health |
52-Week High | $63.82 | $155.80 |
52-Week Low | $16.84 | $117.85 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $9.85B | $213.45B |
Dividend Yield | — | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Gilead Sciences (GILD) trades at $147.92, down 1.67% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $153.13. Recent earnings beat expectations in three consecutive quarters, though Q3 2026 results are pending. The company maintains strong operating cash flow of $10.02B in 2025 and has expanded HIV prevention access through a new PAHO partnership in Latin America.
Investment outlook remains positive with 67% analyst buy ratings and potential upside to price targets, though risks include negative net income margin (-10.64%) projected for 2026 and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, but investors should monitor earnings sustainability and pipeline developments in oncology and HIV therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figma Inc. Class A Common Stock
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
